RAC never existing is a different issue, but it is very unlikely that COH would have spent the money to get Bisantrene back as an available GMP manufactured drug that could be used in a clinical trial. The cost of this is around $6-8 million. Even running a clinical trial using an approved generic drug off-label is hard to get support funding.
The COH could have run clinical trials at anytime after 2019 (we would have even given them Bisantrene for free if they had asked), but they haven’t even considered doing this. Without Race Prof Chen’s discovery would have just been another of the thousands of promising scientific discoveries published every year that never make it to the clinic.
Ann: Zantrene AML trial in Israel advances to Phase 2, page-149
-
- There are more pages in this discussion • 85 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.94 |
Change
0.055(2.92%) |
Mkt cap ! $330.4M | |||
| Open | High | Low | Value | Volume |
| $1.89 | $1.96 | $1.85 | $333.0K | 174.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3105 | $1.94 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.95 | 7574 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |